

## Commercial/Healthcare Exchange PA Criteria

*Effective: July 25, 2018*

**Prior Authorization:** Aimovig

**Products Affected:** Aimovig (erenumab-aooe) Subcutaneous Solution

**Medication Description:** Aimovig (erenumab-aooe) blocks calcitonin gene-related peptide (CGRP), a receptor involved in migraine attacks.

**Covered Uses:** Preventative treatment of migraine in adults.

**Exclusion Criteria:**

1. Concurrent use (for example, during the same time period) of two CGRP inhibitors indicated for the preventative treatment of migraine (for example, Ajovy, Emgality, Nurtec ODT, Vyepti)

**Required Medical Information:**

1. Diagnosis
2. Previous therapies tried and failed

**Age Restrictions:** 18 years of age or older

**Prescriber Restrictions:** N/A

**Coverage Duration:** 12 months

**Other Criteria:**

**Initial Criteria:**

**Migraine Prophylaxis**

1. Patient has clinically diagnosed episodic migraine as defined at least 4 migraine days per month; **AND**
2. Patient has prior usage of at least **TWO** standard prophylactic pharmacologic therapies, each from a different pharmacologic class, used to prevent migraines or reduce migraine frequency including:
  - a. Angiotensin receptor blockers;
  - b. Angiotensin Converting Enzyme Inhibitors;
  - c. Beta-blockers (i.e. propranolol, metoprolol, atenolol);
  - d. Calcium Channel blockers (i.e. verapamil);
  - e. Anti-epileptics (i.e. as topiramate or divalproex sodium);
  - f. Antidepressants (venlafaxine OR a tricyclic antidepressant such as amitriptyline or nortriptyline); **AND**
3. The patient has had inadequate efficacy to both of those standard prophylactic pharmacologic therapies, according to the prescribing physician; **OR**
4. The patient has experienced adverse event(s) severe enough to warrant discontinuation of both of those standard prophylactic pharmacologic therapies, according to the prescribing physician.

**Renewal Criteria:**

1. Positive response to therapy demonstrated by a 50% reduction in monthly migraine days; **AND**
2. The use of acute migraine medications (ie NSAIDs, triptans) has decreased since start therapy; **AND**
3. Patient has an overall improvement in function with therapy

**References:**

1. Aimovig™ injection [prescribing information] Thousand Oaks, CA:Amgen; May 2018

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	07/23/2018
2	Update	Removed Prescriber Restriction Update Other Criteria	Prescriber Restriction Other Criteria	4/11/2019
3	Update	Coverage Duration update to 12 months	Coverage Duration	3/27/2020
4	Update	Removed the following from other criteria:  5.Patient has prior usage in the last 18 months of at least one triptan therapy; <b>AND</b>  6.Patient is intolerant to or, has a contraindication to or, inadequate response from triptan therapy.	Other Criteria	07/01/2021
5	Update	Updated Exclusion criteria: From: 1.Concurrent use with another (CGRP) inhibitor to:  Concurrent use (for example, during the same time period) of two CGRP inhibitors indicated for the preventative treatment of migraine (for example, Aimovig, Ajoovy, Emgality, Nurtec ODT, Vyepti)	Other Criteria	4/5/2022